esomeprazole + bismuth + amoxicillin + tetracycline + furazolidone

This is a combination therapy consisting of five agents—esomeprazole, bismuth, amoxicillin, tetracycline, and furazolidone—used primarily for the eradication of Helicobacter pylori infection. Each component has a distinct mechanism: - Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase in gastric parietal cells. - Bismuth compounds have antimicrobial activity against H. pylori and protect the gastric mucosa. - Amoxicillin is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis. - Tetracycline is a broad-spectrum antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit. - Furazolidone is a nitrofuran antibacterial agent with additional monoamine oxidase inhibitor (MAOI) activity; it interferes with bacterial enzyme systems and has activity against both bacteria and protozoa. This multi-drug regimen targets H. pylori through multiple mechanisms to overcome resistance and improve eradication rates, especially in regions where standard therapies are less effective or resistance rates are high[6][8][10]. Furazolidone's inclusion provides an alternative for cases resistant to other antibiotics[6].